已收盤 11-20 16:00:00 美东时间
+0.040
+3.15%
11月18日,美第奇新星生物技术(MNOV)收平,报1.34美元,成交额7.87万美元,市值6865.18万美元。 行情数据 • 开盘价:1.38美元 • 最高...
11-18 08:12
最新财报显示,美第奇新星生物技术2026财年第3季度实现: 营业收入:13.86万美元 同比:增长12.35% 每股收益:-0.06美元 同比:增长7.41%...
11-14 22:00
11月10日,美第奇新星生物技术(MNOV)收涨0.68%,报1.47美元,成交额7.94万美元,市值7224.5万美元。 行情数据 • 开盘价:1.46美元...
11-10 08:14
11月3日,美第奇新星生物技术(MNOV)收涨2.86%,报1.44美元,成交额6.96万美元,市值7087.86万美元。 行情数据 • 开盘价:1.4美元 ...
11-03 08:11
10月27日,美第奇新星生物技术(MNOV)收涨0.72%,报1.4美元,成交额12.83万美元,市值6890.95万美元。 行情数据 • 开盘价:1.42美元...
10-27 07:14
10月22日,美第奇新星生物技术(MNOV)收涨3.68%,报1.41美元,成交额4.54万美元,市值6940.17万美元。 行情数据 • 开盘价:1.37美元...
10-22 07:19
10月20-22日上海黄浦江畔,2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势,更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:18
MediciNova, Inc. provided an update on its Phase 2 clinical trial evaluating MN-001 (tipelukast) for nonalcoholic fatty liver disease (NAFLD) and hypertriglyceridemia associated with type 2 diabetes mellitus. While the trial did not achieve statistical significance on its primary endpoints, encouraging signals were observed, including improvements in HDL-C, HDL-P, and early reduction in triglycerides. MN-001 was well-tolerated with no serious adv...
10-12 10:00
MediciNova, a clinical-stage biopharmaceutical company, announced that its management will participate in the Maxim Growth Summit on October 12-14, 2026, in New York. Investors can schedule one-on-one meetings with MediciNova's management through their Maxim representative or via a provided link. The company specializes in developing small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases, with its lead asset MN-166 (i...
10-06 10:00